1. Search Result
Search Result
Results for "

serotonin release

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Fluorescent Dye

2

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W100249

    5-Methoxy-6-methyl-2-aminoindan

    5-HT Receptor Neurological Disease
    MMAI is a selective serotonin releaser that can be used in the research of mental illnesses .
    MMAI
  • HY-175721

    Serotonin Transporter Neurological Disease
    UCD0820 is a Serotonin transporter (SERT) inhibitor that acts as a partial serotonin releasing agent (SRA). UCD0820 can be used for depression, addiction and post-traumatic stress disorder (PTSD) research .
    UCD0820
  • HY-175720

    Serotonin Transporter Neurological Disease
    UCD0168 is a Serotonin transporter (SERT) inhibitor that acts as a full serotonin releasing agent (SRA). UCD0168 can be used for depression, addiction and post-traumatic stress disorder (PTSD) research .
    UCD0168
  • HY-W158945

    Serotonin Transporter Neurological Disease
    3-Chloroamphetamine hydrochloride is a derivative of Amphetamine that acts as a central nervous system stimulant by releasing serotonin and dopamine.
    3-Chloroamphetamine hydrochloride
  • HY-172071

    PAL-1046 hydrochloride

    5-HT Receptor Neurological Disease
    Methamnetamine (PAL-1046) hydrochloride is an amphetamine-based psychoactive substance. Methamnetamine hydrochloride causes excessive release of serotonin .
    Methamnetamine hydrochloride
  • HY-W342779

    Dopamine Receptor Neurological Disease
    4-Bromoamphetamine hydrochloride is an amphetamine derivative which acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA) and produces stimulant effects. 4-Bromoamphetamine hydrochloride is highly neurotoxic, producing long-term depletion of serotonin .
    4-Bromoamphetamine hydrochloride
  • HY-129440R

    PDGFR ERK Caspase Metabolic Disease Inflammation/Immunology
    N-(p-Coumaroyl) Serotonin (Standard) is the analytical standard of N-(p-Coumaroyl) Serotonin. This product is intended for research and analytical applications. N-(p-Coumaroyl) Serotonin is a polyphenol isolated from the seeds of safflower and has antioxidative, anti-atherogenic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits PDGF-induced on phosphorylation of PDGF receptor and Ca2+ release from sarcoplasmic reticulum . N-(p-Coumaroyl) Serotonin ameliorates atherosclerosis and distensibility of the aortic wall in vivo and is usually used for the atherosclerosis research .
    N-(p-Coumaroyl) Serotonin (Standard)
  • HY-116680

    5-HT Receptor Cardiovascular Disease Neurological Disease
    LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
    LY53857
  • HY-131556

    p-Iodoamphetamine hydrochloride

    5-HT Receptor Neurological Disease
    4-Iodoamphetamine (p-Iodoamphetamine) hydrochloride is a halogenated amphetamine featuring an iodine atom at the para position of the phenyl group. 4-Iodoamphetamine hydrochloride selectively induces serotonin release and inhibits reuptake by rat brain synaptosomes.
    4-Iodoamphetamine hydrochloride
  • HY-162511

    Dopamine Transporter Serotonin Transporter Others
    IP2015 is an inhibitor for monoamine reuptake, that inhibits the reuptake of dopamine, serotonin (5-HT), and noradrenaline. IP2015 increases release of central dopamine and peripheral nitric oxide (NO), causes the NO-mediated relaxation of erectile tissue, and thus induces erection in rat model .
    IP2015
  • HY-18332C

    Serotonin Transporter Dopamine Transporter Neurological Disease
    DOV-216,303 (Free Base) is a potent triple serotonin, norepinephrine, and dopamine reuptake inhibitor, with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. Has antidepressant-like effects and increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
    DOV-216,303 Free Base
  • HY-135222

    5-Methoxy-6-methyl-2-aminoindan hydrochloride

    5-HT Receptor Neurological Disease
    MMAI (5-Methoxy-6-methyl-2-aminoindan) hydrochloride is a selective serotonin releaser that does not produce psychoactive or hallucinogenic effects in the context of drug discrimination in rats. MMAI hydrochloride induces a behavioral syndrome in rats, including hypokinesia with freezing, spinning, Straub tail, flat posture, and reduced sleep time .
    MMAI hydrochloride
  • HY-106865

    Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol has an anti-ischemic activity. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol can be used for myocardial ischemia research .
    Mivazerol
  • HY-W061043

    Serotonin Transporter Dopamine Transporter Neurological Disease
    DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
    DOV-216,303
  • HY-111066

    Dopamine Receptor Others
    JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.
    JNJ-37822681
  • HY-133858

    5-HT Receptor Neurological Disease
    25N-NBOMe hydrochloride, a 2C-N derivative, is a 5-HT2A and 5-HT2C receptors agonist with Ki values of 0.144 nM and 1.06 nM, respectively. 25N-NBOMe hydrochloride has little to no efficacy at inducing release of preloaded neurotransmitter from recombinant dopamine, serotonin and norepinephrine transporters .
    25N-NBOMe hydrochloride
  • HY-103465B

    Monoamine Transporter Others
    FFN511 (hydrochloride) is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 (hydrochloride) inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 (hydrochloride) directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
    FFN511 hydrochloride
  • HY-103465

    Monoamine Transporter Others
    FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
    FFN511
  • HY-120155

    Sigma Receptor Neurological Disease
    MS-377 is a selective and orally active sigma-1 receptor ligand (Ki=73 nM) with weak affinity for sigma-1 receptor (Ki=6900 nM) and no affinity for any other receptors including dopamine, serotonin, PCP site, glutamate, γ-aminobutylic acid, adenosine, adrenergic receptors, etc. (Ki: >10 μM). MS-377 indirectly modulates the NMDA receptor ion-channel complex. MS-377 is a antipsychotic agent. MS-377 inhibits PCP-induced behaviors by inhibition of the increase in dopamine and serotonin release in the rat medial prefrontal cortex. MS-377 can be used for research of schizophrenia .
    MS-377
  • HY-D2335

    Fluorescent Dye Neurological Disease
    SERTlight is a fluorescent agent that can specifically label serotonergic neuronal cell bodies, dendrites, and axonal projections as fluorescent substrates of the serotonin transporter (SERT). SERTlight is orthogonal to various genetically encoded sensors in terms of optics, pharmacology, and operation, enabling multiple imaging. SERTlight allows the use of GRAB5HT sensors to label distal 5HT axonal projections and simultaneously image the release of endogenous 5HT, providing a new multifunctional molecular tool for studying serotonergic systems .
    SERTlight
  • HY-B1693
    Levomepromazine
    1 Publications Verification

    Methotrimeprazine

    5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine
  • HY-174146

    5-HT Receptor Neurological Disease
    5-HT1A agonist 1 (Compound Ex.37) is a highly selective 5-HT1a receptor agonist (EC50=0.18 nM). 5-HT1A agonist 1 mimicks serotonin binding to the receptor, promotes postsynaptic membrane hyperpolarization, inhibits neuronal hyperexcitability, and reduces the release of anxiety-related neurotransmitters. 5-HT1A agonist 1 is promising for research of neuropsychiatric diseases .
    5-HT1A agonist 1
  • HY-B1693A

    Methotrimeprazine hydrochloride

    5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine hydrochloride
  • HY-P1080

    Calcium Channel Neurological Disease
    ω-Agatoxin IVA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels .
    ω-Agatoxin IVA
  • HY-B1693R

    Methotrimeprazine (Standard)

    Reference Standards 5-HT Receptor Dopamine Receptor Autophagy Histamine Receptor Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Standard) is the analytical standard of Levomepromazine. This product is intended for research and analytical applications. Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine (Standard)
  • HY-P1080A
    ω-Agatoxin IVA TFA
    1 Publications Verification

    Calcium Channel Neurological Disease
    ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA TFA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA TFA has no effect on L-type or N-type calcium channels .
    ω-Agatoxin IVA TFA
  • HY-141554A

    (2S,3S,11bR)-DHTBZ

    Monoamine Transporter Neurological Disease
    (2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki value of 593 nM. (2S,3S,11bR)-Dihydrotetrabenazine inhibits vesicular transport of monoamine neurotransmitters like dopamine and serotonin, reducing their synaptic release. (2S,3S,11bR)-Dihydrotetrabenazine is promising for research of Huntington's chorea and other hyperkinetic disorders .
    (2S,3S,11bR)-Dihydrotetrabenazine
  • HY-111136

    GABA Receptor 5-HT Receptor Dopamine Receptor Histamine Receptor Neurological Disease
    BL-1020 mesylate is the mesylate salt form of BL-1020. BL-1020 mesylate is an antipsychotic agent. BL-1020 mesylate is inhibitor for dopamine receptor and serotonin receptor (5-HT receptor), with Ki of 0.066, 0.062 and 0.21 nM, for D2L, D2S and 5-HT2A receptors, respectively. BL-1020 mesylate is agonist for GABAA receptor with Ki of 3.74 μM, and enhances the GABA release. BL-1020 mesylate exhibits high affinity with histamine receptor (Ki is 0.47 nM). BL-1020 mesylate reduces Amphetamine-induced hyperactivity, with lower catalepsy and sedation. BL-1020 mesylate is blood-brain barrier penetrate .
    BL-1020 mesylate
  • HY-156807

    Serotonin Transporter 5-HT Receptor Neurological Disease
    LY 367265 is a 5-hydroxytryptamine transporter (SERT) inhibitor (IC₅₀ = 3.1 nM) and a 5-HT₂A receptor antagonist (Kᵢ = 0.81 nM). LY 367265 has the inhibitory activity on the norepinephrine transporter (NET) of extremely weak (IC₅₀ > 1000 nM); it has low affinity for subtypes such as 5-HT₁B (Kᵢ = 490 nM) and 5-HT₁D (Kᵢ = 81 nM), showing high selectivity. LY 367265 concentration-dependently enhances of [³H]5-HT efflux (EC₅₀ = 250 nM). LY 367265 antagonizes the contraction response of Sumatriptan (HY-B0121B), indicating its functional antagonistic activity on 5-HT₁D-like receptors. LY 367265 can be used for the study of diseases such as anxiety disorders and post-traumatic stress disorder .
    LY 367265

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: